Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.

Autor: Steinmetz AR; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pierce M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Martini A; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Tholomier C; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Manyam G; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chen Y; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sood A; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Duplisea JJ; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Johnson BA; Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, United States., Czerniak BA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lee BH; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Jagannath C; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX, United States., Yla-Herttuala S; A.I. Virtanen Institute for Molecular Sciences, Kuopio, Finland., Parker NR; A.I. Virtanen Institute for Molecular Sciences, Kuopio, Finland., McConkey DJ; Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, United States., Dinney CP; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Mokkapati S; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Nov 04; Vol. 15, pp. 1387229. Date of Electronic Publication: 2024 Nov 04 (Print Publication: 2024).

Excision of recurrent penile schwannoma with neurovascular bundle sparing: A novel surgical approach.

Autor: Voleti SS; Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA., Warren CJ; Mayo Clinic Arizona Department of Urology, Phoenix, AZ, USA., Parker NR; Mayo Clinic Arizona Department of Urology, Phoenix, AZ, USA., Stanton M; Mayo Clinic Arizona Department of Pathology, Phoenix, AZ, USA., Khan AA; Mayo Clinic Arizona Department of Urology, Phoenix, AZ, USA., Noland SS; Mayo Clinic Arizona Department of Plastic & Reconstructive Surgery, Phoenix, AZ, USA., Punjani N; Mayo Clinic Arizona Department of Urology, Phoenix, AZ, USA.

Publikováno v: Urology case reports [Urol Case Rep] 2023 Jun 12; Vol. 50, pp. 102458. Date of Electronic Publication: 2023 Jun 12 (Print Publication: 2023).

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.

Autor: Mitra AP; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Narayan VM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mokkapati S; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Miest T; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boorjian SA; Department of Urology, Mayo Clinic, Rochester, MN, USA., Alemozaffar M; Department of Urology, Kaiser Permanente Los Angeles, Los Angeles, CA, USA., Konety BR; Department of Urology, Rush Medical College, Chicago, IL, USA., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA., Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, MI, USA., Lerner SP; Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA., Busby JE; Department of Surgery, Prisma Health, University of South Carolina School of Medicine at Greenville, Greenville, SC, USA., Poch M; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Crispen PL; Department of Urology, University of Florida, Gainesville, FL, USA., Steinberg GD; Department of Urology, New York University Langone Health, New York, NY, USA., Schuckman AK; Institute of Urology, University of Southern California, Los Angeles, CA, USA., Downs TM; Department of Urology, University of Wisconsin, Madison, WI, USA., Svatek RS; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Mashni J; Department of Surgical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Lane BR; Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, MI, USA., Guzzo TJ; Division of Urology, University of Pennsylvania, Philadelphia, PA, USA., Bratslavsky G; Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA., Karsh LI; The Urology Center of Colorado, Denver, CO, USA., Woods ME; Department of Urology, Loyola University, Maywood, IL, USA., Brown GA; New Jersey Urology, Bloomfield, NJ, USA., Canter D; Georgia Urology, Atlanta, GA, USA., Luchey A; Department of Urology, West Virginia University Cancer Institute, Morgantown, WV, USA., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Krupski T; Department of Urology, University of Virginia, Charlottesville, VA, USA., Inman BA; Division of Urology, Department of Surgery, Duke University, Durham, NC, USA., Williams MB; Urology of Virginia, Virginia Beach, VA, USA., Cookson MS; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Keegan KA; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Andriole GL; Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine in St Louis, St Louis, MO, USA., Sankin AI; Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA., Boyd A; Boyd Consultants Ltd, Crewe, UK., O'Donnell MA; Department of Urology, University of Iowa, Iowa City, IA, USA., Philipson R; Trizell Ltd, Chinnor, UK., Ylä-Herttuala S; AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland., Sawutz D; FKD Therapies Oy, Kuopio, Finland., Parker NR; AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland., McConkey DJ; Department of Urology, Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA., Dinney CPN; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: cdinney@mdanderson.org.

Publikováno v: European urology [Eur Urol] 2022 Mar; Vol. 81 (3), pp. 223-228. Date of Electronic Publication: 2021 Dec 18.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Autor: Boorjian SA; Department of Urology, Mayo Clinic, Rochester, MN, USA., Alemozaffar M; Department of Urology, Kaiser Permanente Los Angeles, Los Angeles, CA, USA., Konety BR; Department of Urology, University of Minnesota, Minneapolis, MN, USA., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA., Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, MI, USA., Lerner SP; Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Busby JE; Cancer Centers of the Carolinas, Greenville Hospital System, Greenville, SC, USA., Poch M; Department of GU Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Crispen PL; Department of Urology, University of Florida, Gainesville, FL, USA., Steinberg GD; Department of Urology, New York University Langone Health, New York, NY, USA., Schuckman AK; USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Downs TM; Department of Urology, University of Wisconsin, Madison, WI, USA., Svatek RS; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Mashni J Jr; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Lane BR; Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, MI, USA., Guzzo TJ; Division of Urology, University of Pennsylvania, Philadelphia, PA, USA., Bratslavsky G; Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA., Karsh LI; The Urology Center of Colorado, Denver, CO, USA., Woods ME; Department of Urology, University of North Carolina, Chapel Hill, NC, USA., Brown G; New Jersey Urology, Bloomfield, NJ, USA., Canter D; Ochsner Health System, Jefferson, LA, USA., Luchey A; West Virginia University Cancer Institute, Morgantown, WV, USA., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Krupski T; Department of Urology, University of Virginia Cancer Center, Charlottesville, VA, USA., Inman BA; Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Williams MB; Urology of Virginia, Virginia Beach, VA, USA., Cookson MS; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Keegan KA; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Andriole GL Jr; Washington University School of Medicine in St Louis, St Louis, MO, USA., Sankin AI; Department of Urology, Montefiore Medical Center, Bronx, NY, USA., Boyd A; Alan Boyd Consultants, Crewe, UK., O'Donnell MA; Department of Urology, University of Iowa, Iowa City, IA, USA., Sawutz D; FKD Therapies Oy, Kuopio, Finland., Philipson R; Trizell, Chinnor, Oxon, UK., Coll R; Trizell, Chinnor, Oxon, UK., Narayan VM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Treasure FP; Peter Treasure Statistical Services, King's Lynn, UK., Yla-Herttuala S; AI Virtanen Institute University of Eastern Finland and Science Service Center and Gene Therapy Unit, Kuopio, Finland., Parker NR; AI Virtanen Institute University of Eastern Finland and Science Service Center and Gene Therapy Unit, Kuopio, Finland., Dinney CPN; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: cdinney@mdanderson.org.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 107-117. Date of Electronic Publication: 2020 Nov 27.

Development of Large-Scale Downstream Processing for Lentiviral Vectors.

Autor: Valkama AJ; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland.; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Oruetxebarria I; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Lipponen EM; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Leinonen HM; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Käyhty P; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Hynynen H; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Turkki V; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Malinen J; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland., Miinalainen T; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Heikura T; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Parker NR; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Ylä-Herttuala S; Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland., Lesch HP; Kuopio Center for Gene and Cell Therapy, 70210 Kuopio, Finland.; FinVector, 70210 Kuopio, Finland.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2020 Mar 30; Vol. 17, pp. 717-730. Date of Electronic Publication: 2020 Mar 30 (Print Publication: 2020).